Comparison of Icg's Route of Administration During Laparoscopic Cholecystectomy

Not Applicable

• Conditions: Laparoscopic; Cholecystectomy; Post-Op Complication; Indocyanine Green; Intraoperative Complications; Bile Duct Injury; Cholangiography; Cholelithiasis; Bile Duct; Choledocholithiasis; Stone - Biliary
• Interventions: Procedure: Indocyanine Green (ICG) administration

• Registration Number: NCT04908826
• Lead Sponsor: Aristotle University Of Thessaloniki

Brief Summary

The aim of the trial is to compare the routes of administration of indocyanine green (ICG) during laparoscopic cholocystectomy.

Detailed Description

Laparoscopic cholecystectomy is now the method of choice for the treatment of symptomatic and complicated gallstones.

There are two major problems that can occur during and after a laparoscopic cholecystectomy. These are the remaining stones in the bile duct and the iatrogenic injuries of the bile ducts. Iatrogenic bile duct injuries are the most difficult complication of cholecystectomy and are a clinical entity that needs multifactorial treatment as it significantly increases morbidity, mortality and overall cost. Intraoperative cholangiography is used to prevent these complications.

Intraoperative cholangiography is the traditional method of identifying bile duct anatomy during laparoscopic cholecystectomy. This method has the disadvantages that both the patient and the staff are exposed to radiation, while in order to perform it, catheterization of the cystic duct must be performed, which requires surgical procedures that increase the time of the operation, while in some cases it is not technically easy. Finally, with the intraoperative cholangiography, the injuries of the bile ducts are detected, after they have taken place, therefore it helps in their timely diagnosis but does not limit the frequency of their occurrence.

Indocyanine green is a sterile, anionic, water-soluble but relatively hydrophobic tricarbocyanine molecule with a molecular weight of 751.4. It was developed in 1955 at Kodak Laboratories and in 1959 was approved for clinical use by the FDA. It has the property of fluorescing, after its administration, with a maximum absorption at 800 nm after exposure to infrared lighting. Its use offers an image of high clarity and sensitivity, target imaging, with parallel low acoustic emission. Indocyanine green has the following properties and advantages, which make it an important tool in the applications of medical sciences and studies.

Following intravenous administration, it binds to plasma lipoproteins with minimal escape into the interstitial space. Extremely important for its clinical use is the complete excretion through the bile, as well as the non-production of metabolic products. It has low toxicity in the absence of ionization, which in combination with the short half-life of the substance, provides safety for the patient in its use and application in medical and biomedical sciences. It has low costs that in combination with its ease of use facilitates its application. No expensive equipment or large learning curve required. Also the possibility of recurrence with re-administration intraoperatively can offer a number of applications in laparoscopic surgery. It has a low rate of side effects and interactions with other drugs and preparations, a major allergic reaction has been reported in the literature. The first clinical applications of indocyanine green were to assess cardiac function, liver function in cirrhotic patients before hepatectomy, and to examine the retinal vessels.

Its use in laparoscopic cholecystectomy, as already mentioned, is based on its ability to fluoresce when exposed to infrared light and in combination with the fact that when administered intravenously it is concentrated and excreted from the bile offers the possibility of intraoperative, fluorescent cholangiography that aims to identify the elements of the Callot triangle.

This study aims to demonstrate that endocyanin green cholangiography is equivalent to or better than conventional cholangiography for the diagnosis of cholelithiasis and biliary injuries. It is therefore an important clinical application that will probably facilitate surgeons both in the prevention of biliary injuries and in the intraoperative diagnosis of cholelithiasis.

Patients who will undergo laparoscopic cholecystectomy will be randomly divided into 3 (three) groups. The processing of the results will be done in the appropriate way and method. A total of 240 patients will be randomized into three groups of 80. In the first group (A) classical cholangiography will be performed. In group (B) will be performed intravenous fluorescent cholangiography with indocyanine green 6 (six) hours before the start of surgery. In the third group (C) will be performed intraoperative cholangiography with direct administration of indocyanine green to the gallbladder.

Study Timeline

• Study First Submitted: 2021-05-10
• Study First Submitted QC: 2021-05-26
• Study First Posted: 2021-06-01
• Study Start: 2022-01-03
• Status Verified: 2022-03
• Last Update Submitted: 2022-03-09
• Last Update Posted: 2022-03-10
• Primary Completion: 2022-06-01
• Study Completion: 2023-01-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 240

Inclusion Criteria

1. age older than 18 years old
2. laparoscopic cholecystectomy
3. elective surgery

Exclusion Criteria

1. younger than 18 years old
2. no consent to participate to the study
3. history of allergic reaction to iodine products
4. urgent or emergent cholecystectomy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group C (cholangiography with direct administration of icg to the bile duct system during surgery)	Indocyanine Green (ICG) administration	All patients will undergo laparoscopic cholecystectomy. In the third group intraoperative cholangiography will be performed with direct administration of indocyanine green at a dose of 0.03 mg / ml / Kg to the bile duct cyst.
Group A (standard cholangiography during surgery)	Indocyanine Green (ICG) administration	All patients will undergo laparoscopic cholecystectomy. In this group standard cholangiography will be performed during surgery. Standard cholangiography will be performed with selective catheterization of the cystic duct and infusion of a radiolucent substance (non-ionic low osmotic iodine). The category includes drugs such as iohexol, iopamidol, iopromide, ioversol, iobitriol, iomeprol and iodixanol. In our study we will use Xenetix (iobitriol) and perform cholangiography with C-ARM recording.
Group B (cholangiography with iv administration of icg prior to surgery)	Indocyanine Green (ICG) administration	All patients will undergo laparoscopic cholecystectomy. In this group intravenous fluorescent cholangiography with indocyanine green will be given at a dose of 0.3 mg / mL / Kg 6 (six) hours before the start of surgery.The bile duct system will be recorded with a special camera (Karl Storz NIR / ICG).

Primary Outcome Measures

Name	Time	Method
operation duration	intra-operatively	minutes
applicability of the intra-operatively cholangiography	intra-operatively	yes or no
presence of bile duct stones (choledocholithiasis)	intra-operatively	yes or no
successful imaging of biliary system	intra-operatively	The anatomy of the extrahepatic bile ducts will be orally determined by the surgeon and the cases in which the oral description will coincide with the findings of cholangiography or not and where there were differences will be recorded.
intra-operative complications (bleeding, bile duct leakage, bile duct injury)	intra-operatively	presence or absence

Secondary Outcome Measures

Name	Time	Method
ALP	24 hours prior to surgery and 24 hours after the surgery	g/dL
total bilirubin	24 hours prior to surgery and 24 hours after the surgery	mg/dL
SGPT	24 hours prior to surgery and 24 hours after the surgery	g/dL
γ-GT	24 hours prior to surgery and 24 hours after the surgery	g/dL
indirect bilirubin	24 hours prior to surgery and 24 hours after the surgery	mg/dL
WBC	24 hours prior to surgery and 24 hours after the surgery	mm3/L
gender	pre-operatively	male or female
ASA score	pre-operatively	number
age	pre-operatively	years
indication for laparoscopic cholecystectomy	pre-operatively	yes or no
SGOT	24 hours prior to surgery and 24 hours after the surgery	g/dL
direct bilirubin	24 hours prior to surgery and 24 hours after the surgery	mg/dL
INR	24 hours prior to surgery and 24 hours after the surgery	number
body mass index	pre-operatively	kg/m2
aPTT	24 hours prior to surgery and 24 hours after the surgery	seconds
creatinine	24 hours prior to surgery and 24 hours after the surgery	mg/dL
PT	24 hours prior to surgery and 24 hours after the surgery	seconds
TNF-a	24 hours prior to surgery and 24 hours after the surgery	pg/ml
urea	24 hours prior to surgery and 24 hours after the surgery	mg/dL
CRP	24 hours prior to surgery and 24 hours after the surgery	mg/L
procalcitonin	24 hours prior to surgery and 24 hours after the surgery	mg/dL
IL-6	24 hours prior to surgery and 24 hours after the surgery	pg/ml
ESR	24 hours prior to surgery and 24 hours after the surgery	mm

Trial Locations

Locations (1)

General Hospital of Thessaloniki "G. Papanikolaou"; 🇬🇷 Thessaloniki, Greece